188 related articles for article (PubMed ID: 30916480)
1. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
Soya E; Makowski C; Blaise S
Int Wound J; 2019 Aug; 16(4):897-902. PubMed ID: 30916480
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Chaine B; Neonato MG; Girot R; Aractingi S
Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
5. Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Brandow AM; Wandersee NJ; Dasgupta M; Hoffmann RG; Hillery CA; Stucky CL; Panepinto JA
Br J Haematol; 2016 Oct; 175(2):237-245. PubMed ID: 27539682
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
7. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.
Lobo CL; Pinto JF; Nascimento EM; Moura PG; Cardoso GP; Hankins JS
Br J Haematol; 2013 Jun; 161(6):852-60. PubMed ID: 23590693
[TBL] [Abstract][Full Text] [Related]
8. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
9. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
Lanzkron S; Strouse JJ; Wilson R; Beach MC; Haywood C; Park H; Witkop C; Bass EB; Segal JB
Ann Intern Med; 2008 Jun; 148(12):939-55. PubMed ID: 18458272
[TBL] [Abstract][Full Text] [Related]
11. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
12. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
13. Hydroxycarbamide for sickle-cell anaemia in infancy.
Weatherall DJ
Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
[No Abstract] [Full Text] [Related]
14. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
15. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
16. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
[TBL] [Abstract][Full Text] [Related]
17. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
Rees AL
J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
[TBL] [Abstract][Full Text] [Related]
19. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
20. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
